效应器
细胞生物学
生物
免疫系统
细胞毒性T细胞
细胞溶解
白细胞介素15
细胞因子
免疫学
T细胞
白细胞介素21
白细胞介素3
细胞分化
免疫疗法
抗原
白细胞介素12
嵌合抗原受体
细胞毒性
受体
癌症研究
癌症免疫疗法
作者
David Cunningham,Junquan Liu,İnci Cevher Zeytin,Daniela Cerda,Nisha Ghatwai,Amy N. Courtney,Linjie Guo,Purva Rathi,Cathy Qizhi Yao,Ningyan Zhang,Zhiqiang An,Andras Heczey
标识
DOI:10.1158/2326-6066.cir-25-0609
摘要
Chimeric antigen receptor (CAR) T cells have robust antitumor activity against hematologic malignancies and have the potential to benefit patients with solid tumors. Immune recognition of murine proteins expressed in adoptively transferred T cells and lack of homeostatic cytokines in the tumor microenvironment can limit the expansion and persistence of CAR T cells. CARs generated only from human sequences could reduce the risk of immune-mediated rejection and interleukin-15 (IL15), which promotes T-cell survival and fitness, may improve the expansion and persistence of CAR T cells. In this study, we report a CAR construct (ABBz) assembled from human sequences including a single-chain variable fragment (scFv) specific to ALPPL2. This binder was selected through an unbiased, high-throughput screen of a human antibody-derived, phage-displayed scFv library based on binding specificity, stringency, and low dissociation constant. We demonstrated specificity to the antigen, effective cytolytic function, and cytokine production in ABBz T cells. We showed NK-like effector differentiation with sustained proliferative capacity specific to secreted IL15 coexpression in ABBz T cells. Lastly, we demonstrated that ABBz CAR T cells had robust antitumor activity, which was further enhanced through IL15 co-expression, resulting in NK-like effector differentiation with increased cytotoxicity and superior expansion capacity due to reduced apoptosis of CAR T cells. These results demonstrate that IL15 co-expression can promote effector differentiation while maintaining the proliferative capacity of huALPPL2-CAR T cells and provide a foundation for further clinical development of IL15 co-expressing huALPPL2-CAR T cells in patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI